ctDNA-Guided Immunotherapy De-escalation for Advanced Cervical Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if a ctDNA blood test can help guide treatment to use less immunotherapy in patients with advanced or recurrent cervical cancer. It's looking at which patients might safely reduce treatment based on their cancer's genetic signals in the blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 with cervical cancer that is either stage IVB and hasn't been treated, or a recurrence that hasn't been treated.
- Your cancer type must be squamous cell, adenocarcinoma, or adenosquamous (the most common types).
- You must have at least one tumor that can be measured on scans and be in fairly good health (ECOG score 0 or 1, meaning you can do daily activities).
- Your blood counts, kidney function, and liver function must be within certain limits (your doctor will check this).
- You cannot have had immunotherapy before, active autoimmune disease, or active infections like HIV or hepatitis that are not well controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests whether using a blood test for tumor DNA (ctDNA) can help decide who needs more chemotherapy after surgery for advanced stomach cancer. The goal is to personalize treatment and avoid unnecessary side effects.
This trial tests a personalized blood test that looks for tumor DNA to monitor cervical cancer and help guide treatment decisions. It is for people with advanced or returning cervical cancer who haven't started treatment yet.
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemoradiation for cervical cancer that has spread to a few other places in the body. It aims to see if this combination can help control the cancer better.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
Hear when a new Uterine Cervical Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.